Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
14 vs 24 Weeks HCV Treatment for Genotype 2/3
NCT00308048Phase 3Completed
- Sponsor
- Ullevål University Hospital
- Start
- Mar 2004
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b and ribavirin in hepatitis C (HCV) (3 arms), sponsored by Ullevål University Hospital. Primary endpoint: Sustained Virological Response. Started Mar 2004; status: completed.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00308048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00308048.